Before diving into injection techniques, let's understand what semaglutide is and how it works in your body
Here's how they compare: Semaglutide (GLP-1 agonist) Mechanism: Single-action GLP-1 receptor agonist FDA status: Approved for type 2 diabetes and chronic weight management Expected weight loss: 15-20% of body weight in clinical trials Administration: Once-weekly injection Best for: Patients starting their weight loss journey seeking proven, well-studied medication Tirzepatide (dual GIP/GLP-1 agonist) Mechanism: Targets both GIP and GLP-1 receptors for enhanced metabolic effect FDA status: Approved for type 2 diabetes and chronic weight management Expected weight loss: Up to 22% of body weight in clinical trials Administration: Once-weekly injection Best for: Patients seeking more aggressive fat loss with dual-action metabolic support Retatrutide (triple agonist, not yet available) Mechanism: Targets GLP-1, GIP, and glucagon receptors FDA status: Not FDA-approved
Our weight loss medication can achieve impressive changes, especially if the patient combines it with a healthy diet
Despite no longer being a general exclusion, an insurance provider may not include Ozempic or Wegovy on their prescription drug plan formulary
Dib LH, Ortega MT, Fleming SD, Chapes SK, Melgarejo T (2014) Bone marrow leptin signaling mediates obesity-associated adipose tissue inflammation in male mice